> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 4 Observations in Dr. Reddy’s Inspection
- URL: https://www.fdaweb.com/4-observations-in-dr-reddys-inspection/
- Published: 2024-06-20T12:00:00.000Z
- Updated: 2026-09-14T14:33:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157212

A 5/30-6/7 FDA inspection at the Dr. Reddy’s Laboratories active pharmaceutical ingredient manufacturing facility in Andhra, Pradesh, India has four inspection observations. FDA has released the form FDA-483 issued following the inspection with these observations:

- failure to validate or verify analytical methods under the actual conditions of use;
- failure to ensure that manufacturing processes are maintained in a validated state;
- failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed; and
- failure to ensure that materials are not released before the satisfactory completion of evaluation by the quality unit.